Abstract

Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
Siegfried Matthias Huhn ...
The Lancet Respiratory Medicine | VOL. 9
Siegfried Matthias Huhn, et. al.Siegfried Matthias Huhn ...
30 Mar 2021
The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic
Alex West ... Thomas Simpson
-
Alex West, et. al.Alex West ... Thomas Simpson
07 Sep 2020
The burden of progressive fibrotic interstitial lung disease across the UK.
Philip L Molyneaux ... Ryan Miller
The European respiratory journal | VOL. 58
Philip L Molyneaux, et. al.Philip L Molyneaux ... Ryan Miller
07 Mar 2021
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
Jeffrey J Swigris ... Aryeh Fischer
BMJ Open Respiratory Research | VOL. 8
Jeffrey J Swigris, et. al.Jeffrey J Swigris ... Aryeh Fischer
01 Dec 2021
View more papers

More From: The Lancet Respiratory Medicine

Paper Title
Journal
Date
Author
Continuous positive airway pressure is here to stay
Atul Malhotra ... Jeremy H Pettus
The Lancet Respiratory Medicine | VOL. -
Atul Malhotra, et. al.Atul Malhotra ... Jeremy H Pettus
01 May 2024
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
Robert P Frantz ...
The Lancet Respiratory Medicine | VOL. -
Robert P Frantz, et. al.Robert P Frantz ...
01 May 2024
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
Eric Lim ... Chris A Rogers
The Lancet Respiratory Medicine | VOL. 12
Eric Lim, et. al.Eric Lim ... Chris A Rogers
01 May 2024
MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma
Federica Grosso ... Alessandra Curioni-Fontecedro
The Lancet Respiratory Medicine | VOL. 12
Federica Grosso, et. al.Federica Grosso ... Alessandra Curioni-Fontecedro
01 May 2024
View more papers